Lates News

According to the AI flash news, Open Source Securities issued a research report on April 1, giving Kanglong Huacheng (300759.SZ) a "buy" rating. The reasons for the rating mainly include: 1) The quarterly performance in 2025 continues to grow compared to the previous quarter, the quality of profits steadily improves, and there is hope for accelerated growth in 2026; 2) In 2026, the company signed a large-scale small molecule CDMO order with MNC, further enhancing the certainty of company performance; 3) Clinical business grows against the trend, and the ability to provide services in large molecules and cell and gene therapy continues to improve. (Daily Economic News)